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The D113N mutation in the RING E3 
ubiquitin protein ligase gene is not associated 
with ex vivo susceptibility to common 
anti-malarial drugs in African Plasmodium 
falciparum isolates
Mathieu Gendrot1,2, Francis Tsombeng Foguim1,2, Marie Gladys Robert1,2, Rémy Amalvict1,2,3, 
Joel Mosnier1,2,3, Nicolas Benoit1,2,3, Marylin Madamet1,2,3, Bruno Pradines1,2,3* 
and the French National Reference Centre for Imported Malaria Study Group
Abstract 
Background: Plasmodium falciparum resistance to artemisinin-based combination therapy has emerged and spread 
in Southeast Asia. In areas where artemisinin resistance is emerging, the efficacy of combination is now based on part-
ner drugs. In this context, the identification of novel markers of resistance is essential to monitor the emergence and 
spread of resistance to these partner drugs. The ubiquitylation pathway could be a possible target for anti-malarial 
compounds and might be involved in resistance. Polymorphisms in the E3 ubiquitin-protein ligase (PF3D7_0627300) 
gene could be associated with decreased in vitro susceptibility to anti-malarial drugs.
Methods: Plasmodium falciparum isolates were collected from patients hospitalized in France with imported malaria 
from a malaria-endemic country from January 2015 to December 2016 and, more particularly, from African French-
speaking countries. In total, 215 isolates were successfully sequenced for the E3 ubiquitin-protein ligase gene and 
assessed for ex vivo susceptibility to anti-malarial drugs.
Results: The D113N mutation in the RING E3 ubiquitin-protein ligase gene was present in 147 out of the 215 samples 
(68.4%). The  IC50 values for the ten anti-malarial drugs were not significantly different between the wild-type and 
mutant parasites (p values between 0.225 and 0.933). There was no significant difference in terms of the percentage 
of parasites with decreased susceptibility between the D113 wild-type and the 133N mutated P. falciparum strains (p 
values between 0.541 and 1).
Conclusion: The present data confirmed the absence of the association between polymorphisms in the RING E3 
ubiquitin-protein ligase gene and the ex vivo susceptibility to common anti-malarial drugs in African P. falciparum 
isolates.
Keywords: Malaria, Plasmodium falciparum, Anti-malarial drug, In vitro, Resistance, Molecular marker, RING E3 
ubiquitin-protein ligase gene
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Background
Plasmodium falciparum resistance to most anti-malar-
ial drugs has emerged in Southeast Asia and spread 
to Africa [1, 2]. Since 2005, the World Health Organi-
zation (WHO) has recommended artemisinin-based 
combination therapy (ACT) as first-line treatment for 
uncomplicated malaria and intravenous artesunate for 
the treatment of severe malaria. However, artemisinin 
derivative resistant P. falciparum strains have emerged in 
western Cambodia, Myanmar and Thailand and through-
out Southeast Asia [3–8]. This resistance has resulted 
in a delayed parasite clearance in patients treated with 
artesunate monotherapy or ACT therapy [3, 4]. In areas 
where artemisinin resistance is emerging, combination 
efficacy is based now on partner drugs. In this context, 
the discovery of novel markers of resistance is essential to 
monitor the emergence and spread of resistance to these 
partner drugs.
The ubiquitylation pathway is one of the major path-
ways used by all eukaryotic organisms to regulate pro-
tein abundance and protein activities in their cells. The 
molecular modification of proteins by ubiquitin, called 
ubiquitylation, is one of the main changes in post-trans-
lational events that are essential to most cellular pro-
cesses. Ubiquitin is a 76-amino-acid polypeptide that is 
preserved in eukaryotic organisms, including Plasmo-
dium spp. A single ubiquitin may bond covalently to a 
lysine residue on a protein through a complex enzymatic 
cascade involving activating, conjugating and ligase 
enzymes. Several ubiquitins can be bound to lysine resi-
dues on a single protein. Furthermore, ubiquitins can be 
bound to each other in polyubiquitin chains. At least four 
ubiquitins are required to designate the protein to a pro-
teasome. To bind those ubiquitins, a multi-enzyme com-
plex containing an E1 ubiquitin-activating enzyme, an E2 
ubiquitin-conjugating enzyme and the E3 ubiquitin-pro-
tein ligase is involved (Fig. 1) [9, 10].
Ubiquitylation begins with the use of ATP by the 
E1 enzyme to adenylate its carboxyl terminus, allow-
ing a molecule of ubiquitin to be transferred on the E1 
enzyme active-site cysteine and resulting in a thioester 
bond between the E1 enzyme and ubiquitin. Afterward, 
a trans-thioesterification occurs with the E2 enzyme, 
which carries out the transfer of the E1 enzyme ubiquitin 
to a conserved cysteine on the E2 enzyme. In the end, the 
E3 enzyme removes the E2 bonded ubiquitin to create an 
isopeptide bond between the C-terminal glycine on ubiq-
uitin and the epsilon-amino group of the lysine residue 
on the targeted protein. The target substrate is specific to 
the E3 ligase enzyme. The E3 ligase enzyme must bind at 
least four residues for proteasome addressing.
Three types of E3 ligase enzymes are described as 
follows: the homologous to E6-associated protein 
C-terminus (HECT) ligases, really interesting new gene 
(RING) fingers and finally, U-box E3 ligases. The lat-
ter type of ligase plays a primordial role in substrate 
specificity.
The ubiquitylation pathway could be a possible target 
for anti-malarial compounds and might be involved in 
the resistance of malaria [11, 12]. Previous publications 
using a genome-wide association study (GWAS) showed 
mutations in the E2 ubiquitin-conjugating enzyme gene 
(PF3D7_1243700) and the HECT E3 ubiquitin ligase 
gene (PF3D7_0826100) in Senegalese isolates that 
showed pyrimethamine resistance [13]. Furthermore, an 
HECT E3 ubiquitin ligase gene polymorphism might be 
involved in quinine- and quinidine-reduced susceptibil-
ity [14]. Additionally, P. falciparum strains carrying the 
mutant D113N allele for the E3 ubiquitin-protein ligase 
(PF3D7_0627300) gene were found to be less susceptible 
in  vitro to chloroquine and amodiaquine [15]. Ribacke 
et  al. used population genetics approaches to identify 
genes under positive drug selection. One of them was the 
RING ubiquitine ligase with the D113N mutation. They 
proved no difference in growth between parasites bear-
ing the mutation and those which do not, but the mutant 
strains were less susceptible to CQ and amodiaquine. 
Parasite clones were then matched in competition exper-
iments with the drugs and those carrying the muta-
tion out-competed the wild types clones, suggesting the 
involvement of D113N mutation as a major involvement 
in ubiquitylation cascade and adaptive response to drug 
pressure. Another study showed no significant associa-
tion between the D113N mutation and ex  vivo reduced 
susceptibility to most conventional anti-malarial drugs, 
except a trend with reduced susceptibility to piperaquine 
in P. falciparum Senegalese isolates, but the major limita-
tions of this study was the low number of isolates and the 
geographical provenance of them [16].
The objective of the current study was to analyse pol-
ymorphisms of the E3 ubiquitin-protein ligase gene 
(PF3D7_0627300) in P. falciparum African isolates, more 
particularly the D113N mutation and to evaluate the 
association of this polymorphism with ex vivo suscepti-
bility to chloroquine (CQ), quinine (QN), monodeseth-
ylamodiaquine (DQ), mefloquine (MQ), lumefantrine 
(LMF), piperaquine (PPQ), pyronaridine (PND), dihy-
droartemisinin (DHA), artesunate (AS) and doxycycline 
(DOX) to confirm previous data.
Methods
Patients and sample collection
In total, 215 P. falciparum isolates were successfully 
sequenced for the E3 ubiquitin-protein ligase gene and 
assessed for ex vivo susceptibility to anti-malarial drugs. 
They were collected from patients hospitalized in France 
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with imported malaria from a malaria-endemic country 
from January 2015 to December 2016 and, more par-
ticularly, from African French-speaking countries such 
as Côte d’Ivoire, Cameroon, Central African Republic, 
Republic of Congo, Guinea, Burkina Faso, Togo, Gabon 
and Senegal. The samples were sent from different civil-
ian or military hospitals of the French National Reference 
Centre for Imported Malaria network (Aix en Provence, 
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Fig. 1 Mechanism of the ubiquitin pathway and the transfer role of the ubiquitin protein ligase E3
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Bordeaux, Marseille, Montpellier, Nice, Toulon and 
Toulouse) to the French National Reference Centre for 
Malaria (IRBA, IHU Méditerranée Infection Marseille). 
The parasitaemia, ranging from 0.005 to 9.5%, was esti-
mated on thin blood smears stained by eosin and meth-
ylene blue using a  RAL® kit (Réactifs RAL, Paris, France). 
The diagnosis of P. falciparum mono-infection was con-
firmed by real-time PCR (LightCycler 2.0, Roche Group, 
Switzerland) as previously described [17].
Drugs
CQ, QN, DHA and DOX were obtained from Sigma 
(Saint Louis, MO, USA). DQ was from the WHO 
(Geneva, Switzerland), and MQ was purchased from 
Roche (Paris, France). LMF was from Novartis Pharma 
(Basel, Switzerland), and AS, PPQ and PND were from 
Shin Poong Pharm Co. (Seoul, Korea). QN, DQ, MQ, 
DHA, AS, PPQ and DOX were first dissolved in metha-
nol and then diluted in water to final concentrations that 
ranged from 6 to 3149  nM for QN; 1.9 to 1988  nM for 
DQ; 1.5 to 392 nM for MQ; 0.1 to 107 nM for DHA and 
AS; 1.9 to 998 nM for PPQ and 0.5 to 497 µM for DOX. 
CQ and PND were resuspended and diluted in water 
to final concentrations ranging from 6 to 3231  nM and 
0.4 to 199  nM, respectively. LMF was resuspended and 
diluted in ethanol to obtain final concentrations ranging 
from 0.6 to 310 nM.
Ex vivo assay
The susceptibility of the 215 isolates to the ten anti-
malarial drugs was assessed without culture adaptation. 
A total of 100  µL of parasitized erythrocytes (final par-
asitaemia at 0.5% and a final haematocrit at 1.5%) was 
aliquoted into 96-well plates that were pre-dosed with a 
concentration gradient of anti-malarial drugs (CQ, QN, 
MQ, DQ, LMF, DHA, AS, PPQ, PND and DOX). The 
plates were incubated for 72 h in controlled atmosphere 
at 85%  N2, 10%  O2, 5%  CO2 and 37 °C. The drug suscepti-
bility assay was done using the HRP2 ELISA-based assay 
Malaria Ag Celisa kit (ref KM2159, Cellabs PTY LDT, 
Brookvale, Australia) as previously described [18].
Each batch of plates was validated using the CQ-resist-
ant W2 strain (isolated in Indochina; obtained from MR4, 
VA, USA) in four independent experiments using the 
same conditions described below. The mean 50% inhibi-
tory concentration  (IC50) values for the chloroquine-
resistant W2 strain for the different batches used over 
2 years were 484 ± 40 nM for CQ, 388 ± 29 nM for QN, 
97 ± 18 nM for DQ, 1.0 ± 0.4 nM for LMF, 26.3 ± 3.1 nM 
for MQ, 54.1 ± 5.4  nM for PPQ, 20.4 ± 3.4  nM for 
PND, 2.5 ± 0.4  nM for DHA, 1.5 ± 0.3  nM for AS and 
11.5 ± 1.9  µM for DOX. A comparison of the W2 sus-
ceptibility data of the ten anti-malarial drugs between 
the different batches of plates indicated that there was 
no significant difference in the responses to antimalarial 
drugs over the 2  years (0.583 < p < 0.993). The polymor-
phic genetic markers msp1 and msp2 and microsatellite 
markers specific to P. falciparum were genotyped at least 
once a month to verify W2 clonality [19, 20].
The cut-off values for the reduced in vitro susceptibil-
ity or resistance were as follows: 100 nM (CQ), 800 nM 
(QN), 80 nM (DQ), 30 nM (MQ), 150 nM (LMF), 135 nM 
(PPQ), 60 nM (PND), 10.5 nM (DHA and AS) and 35 µM 
(DOX) [21, 22].
Gene sequence polymorphism analysis
The total genomic DNA of each isolate was isolated using 
the QIAamp DNA Blood Mini Kit according to the man-
ufacturer’s recommendations (Qiagen, Germany). The 
E3 ubiquitin-protein ligase gene (PF3D7_0627300) is 
a 1349  bp gene whose the -5′ end region was amplified 
by PCR using the following primer pairs: 5′-AAT-GGT-
CCA-GAA-GAA-GAT-TAT-3′ and 5′-ATT-TCG-AAT-
TAT-CTT-CTA-CAT-C-3′. The -3′ region was not 
sequenced because the objective of the study focused 
on the previous findings concerning the D113N muta-
tion only [15]. The reaction mixture contained 200 ng of 
genomic DNA, 0.32 µM of each primer, 1× final of reac-
tion buffer (750 mM of Tris–HCl, 200 mM of  (NH4)2SO4, 
0.1% (v/v) Tween 20 and stabilizer, pH 8.8), 2.5  mM of 
 MgCl2, 200 µM of dNTP mixture and 0.2 U of Hot Dia-
mond  Taq® polymerase (Eurogentec) in a final volume 
of 25  µL. The thermal cycler (T3 Biometra) was pro-
grammed as follows: 10  min at 95  °C, then 40 cycles of 
30 s at 95 °C, 45 s at 45 °C, 90 s at 72 °C and a final exten-
sion step of 10 min at 72 °C. The purified amplicons were 
sequenced using PCR primers and the sequencing primer 
5′-AAT-ACT-TAT-GAT-ATG-ACA-AGT-GA-3′ on an 
ABI Prism 3100 analyser (Applied Biosystems) according 
to the manufacturers’ instructions. The sequences were 
analysed using BioEdit, version 7 (Ionis Pharmaceuticals, 
California, USA) to identify the D113N mutation.
Statistical analysis
All the statistical studies, dot plots and the Africa map 
were created using the R software (R Core Team, Vienna, 
Austria).
Results and discussion
The  IC50 of the 215 isolates ranged from 6.27 to 500.6 nM 
for CQ, 5.29 to 690.11 nM for QN, 1.9 to 196.43 nM for 
DQ, 0.33 to 6.96 nM for LMF, 2.4 to 173.43 nM for MQ, 
7.5 to 128.7 nM for PPQ, 0.8 to 122.96 nM for PND, 0.09 
to 28.11 nM for DHA, 0.1 to 19 nM for AS and 0.46 to 
44.89 µM for DOX. The global distribution of P. falcipa-
rum isolates  IC50 is shown in Fig. 2.
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Fig. 2 Dot plot of the  IC50 total distribution of each Plasmodium falciparum isolate for chloroquine (CQ), quinine (QN), monodesethylamodiaquine 
(DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) and doxycycline 
(DOX). Each dot is for an  IC50 isolate, blue dots represent the wild D113 isolates and red dots the mutant 113N isolates. The black bar indicates the 
threshold for parasites with reduced susceptibility
Fig. 3 Repartition of the D113N mutation per its country of origin. The percentage of the D113N mutation in the E3 ubiquitin protein ligase gene 
(green to red coloration)
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Among the 215 isolates, 65.9% of the parasites showed 
reduced ex vivo susceptibility to MQ, 32.7% to CQ, 19,3% 
to DOX, 16,3% of DHA, 9.0% of DQ, 8,4% to AS and 4,7% 
to PND. The data concerning the decrease of the suscep-
tibility to DHA and AS should be analysed with caution. 
The  IC50 were estimated by a standard ex vivo test. Ring-
stage survival assay (RSA), which is a better indicator of 
in  vitro artemisinin resistance, should have been per-
formed. Clinical resistance to artemisinin was manifested 
by an increase in the ring-stage survival rate after contact 
with artemisinin [23–25].
The D113N mutation of the RING E3 ubiquitin-protein 
ligase gene was present in 147 of the 215 samples (68.4%). 
The repartition of the D113N mutation per countries of 
origin is presented in Fig.  3. The D113N mutation was 
present in 69.6% of the isolates collected in 2015 (78 out 
of 112) and 66.9% in 2016 (69 out of 103). There was no 
significant difference between the 2  years and the pro-
portion of mutant 113N isolates (p value = 0.7854, Chi 
squared test with Yates continuity correction).
A new mutation, E237D, was identified in a single iso-
late and conformed twice. This isolate showed the follow-
ing  IC50: 10.3 nM for PPQ, 28.7 nM for CQ, 121.4 nM for 
QN, 8.9 nM for DQ, 0.6 nM for LMF, 21.6 nM for MQ, 
5.2  nM for PND, 5.3  nM for DHA, 5.8  nM for AS and 
Table 1 Ex vivo susceptibilities of 215 African Plasmo-
dium falciparum isolates to chloroquine (CQ), quinine (QN), 
monodesethylamodiaquine (DQ), mefloquine (MQ), lume-
fantrine (LMF), piperaquine (PPQ), pyronaridine (PND), 
dihydroartemisinin (DHA), artesunate (AS) and doxycy-
cline (DOX) according to the D113N mutation in the RING 
E3 ubiquitin protein ligase (PF3D7_0627300) gene
a Geometric mean inhibitory concentration 50%
b Minimum and maximum value for each drug
c p values were determined by the Student t test test
Drug Wild-type D113 (31.6%) Mutated 113N (68.4%) p  valuec
Mean ICa50 Min 
and  maxb
Mean  IC50 Min 
and  maxb
CQ 75.5 [6.3–791.6] 75.1 [11.7–615.9] 0.933
QN 128.2 [5.3–631] 124.8 [9.5–690.1] 0.824
DQ 30.3 [1.9–251.5] 30.4 [6.3–196.4] 0.830
MQ 32.9 [5.5–173.4] 40.2 [2.4–172.6] 0.225
LMF 1.33 [0.4–15.1] 1.35 [0.33–16.7] 0.532
PPQ 31.9 [6.8–128.7] 34.0 [7.5–127.5] 0.398
PND 17.1 [1.67–89.2] 15.7 [0.8–123.0] 0.896
DHA 4.02 [0.09–21.1] 3.90 [0.2–28.1] 0.646
ASU 3.64 [0.21–23.6] 3.57 [0.1–21.2] 0.851
DOX 16.8 [0.46–51.1] 16.4 [0.79–49.9] 0.463
p=0,8822 
p=1 p=1 
p=1 
p=0,5414 
p=1 
p=0,586 
p=1 
p=0,5955 
p=1 
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Fig. 4 Comparison of the prevalences of Plasmodium falciparum isolates with reduced susceptibility to chloroquine (CQ), quinine (QN), monode-
sethylamodiaquine (DQ), mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ), pyronaridine (PND), dihydroartemisinin (DHA), artesunate (AS) 
and doxycycline (DOX) according to the D113N mutation in the E3 ubiquitin protein ligase gene. p values were determined using Fisher’s exact test
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21.6 µM for DOX. This mutant parasite was susceptible 
to all the anti-malarial drugs tested.
The  IC50 values for the ten anti-malarial drugs were not 
significantly different between the wild-type and mutant 
parasites (p values between 0.225 and 0.933) (Table  1). 
The distribution of the  IC50 values for the ten anti-malar-
ial drugs is presented in blue in Fig. 2 for the D113 wild-
type parasites and in red for the 113N mutant parasites.
The isolates were categorized as susceptible or pre-
senting ex  vivo reduced susceptibility to the different 
anti-malarial drugs. There was no significant difference 
between the proportion of D113 wild-type parasites and 
113N mutated parasites showing reduced ex  vivo sus-
ceptibility to the different drugs used (p values between 
0.541 and 1) (Fig. 4).
Polymorphisms of the RING E3 ubiquitin-protein 
ligase gene seem to be uniformly distributed, regard-
less of the African origin of the P. falciparum isolates. 
Among the 215 isolates, 52 came from Cameroon, and 
41 were from Côte d’Ivoire. The parasites were mutant in 
65 and 66% of the isolates, respectively. Countries with 
a low number of collected samples ranging from 1 to 10 
showed a mean of 66.9% of mutant parasites. Countries 
with a number of collected isolates above 10 (except 
Cameroon and Côte d’Ivoire) showed a mean of 74% for 
the 113N mutant strains.
The emergence of resistance to ACT in Southeast Asia 
[3, 4], even to the most recently commercialized DHA-
PPQ in Cambodia [5–8], requires the identification 
of new molecular markers of resistance to ACT part-
ner drugs for monitoring the emergence and spread of 
resistance.
Previous studies showed that P. falciparum strains car-
rying the 113N mutant allele for the E3 ubiquitin-protein 
ligase gene were less susceptible ex vivo to CQ and DQ, 
and that all the Senegalese isolates with reduced sus-
ceptibility to PPQ were mutants [15, 16]. Although the 
D113N mutation was found in a large number of sam-
ples (n = 147, 68.4%), this mutation was not found to be 
involved in the susceptibility modulation to common 
anti-malarial drugs. The distribution of the  IC50 values 
for all ten anti-malarial drugs tested did not show a sig-
nificant difference between the D113 wild-type and 113N 
mutant groups. The decrease in the ex vivo susceptibility 
to CQ and DQ previously observed in genetically modi-
fied parasites was not found in these field African iso-
lates [15]. This could be explained by the use of cloned 
parasites in the study of Ribacke et al., while African field 
isolates were assessed in the present study. The difference 
between clones and field parasites may induce differences 
between in vitro development of mutations and reduced 
susceptibility and wild isolates showing different patterns 
of gene sequence regulation and expression. There was 
no significant difference in the proportion of parasites 
with decreased susceptibility to PPQ between the D113 
wild-type and the mutated 113N P. falciparum strains in 
contrary to previous findings [16].
Conclusion
The ubiquitylation pathway, a key in post-translational 
regulation in eukaryotes, could be a possible target for 
anti-malarial compounds [11, 12, 26]. However, the 
present data confirmed the absence of an association 
between polymorphisms in the RING E3 ubiquitin-pro-
tein ligase gene and the ex vivo susceptibility to common 
anti-malarial drugs in African P. falciparum isolates.
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